chemotherapy, surgery, and radiation. Investors associate cancer immunotherapy with forerunner Dendreon Corporation (NASDAQ: DNDN ), whose PROVENGE vaccine shocked health plans with its exorbitant price that only extended life a few months
Dendreon ( DNDN -33.5% ) Q2 results : Revenues: $82.2M (+12.1%); Operating Expenses: $83.9M (-34.7%); Net Loss
Dendreon (NASDAQ: DNDN ): Q2 EPS of -$0.10 beats by $0.10 . Revenue of $82.2M (+12.1% Y/Y) in-line. Shares -22.6% PM. Press Release Post your comment!
Dendreon ’s high debt load and ..... viability uncertain. Dendreon 's limited sales and ..... know-how may hamper Provenge 's uptake, and its ..... immunotherapy for cancer, Provenge represents a nontoxic ..... treatments on the market. Provenge was recently approved ..... stewardship rating for Dendreon until we see evidence
Dendreon reported second-quarter results ..... than our expectations, with solid Provenge sales. However, the ongoing lack ..... moat, negative trend ratings. Dendreon reported $82.2 million in Provenge sales for the quarter, a solid
investment community (given the recent failure of Dendreon 's pricey prostate cancer drug to live up ..... community following the recent failure of Dendreon 's DNDN pricey prostate cancer drug Provenge to live up to sales expectations. Although
Dendreon reported first-quarter results ..... expectations, with continued sluggish Provenge sales and lack of clarity on plans ..... moat, negative trend ratings. Dendreon reported $68.8 million in Provenge sales for the quarter, a slight
Dendreon reported fourth-quarter results ..... expectations. The stabilization of Provenge revenue and the announcement of the ..... estimate and our no-moat rating. Dendreon reported $74.8 million in Provenge sales for the quarter, up 10
(Reuters) - Biotechnology company Dendreon Corp said it would start selling its prostate cancer vaccine Provenge in Europe, sending its shares up nearly 15 percent in premarket trading.
Dendreon on Monday announced preliminary Provenge revenue for the fourth quarter ..... increasing competition in Provenge 's prechemotherapy indication ..... the current trajectory of Provenge 's sales, we think Dendreon will need to tap the equity